Skin & aging Neurotransmitter-inhibiting peptide
Acetyl octapeptide-3
Regulatory status
Status at a glance
503A compounding status
Not nominated
We found no pending nomination for the 503A bulks list. Unless the substance has another legal pathway (for example, a USP monograph or use in an FDA-approved drug), 503A pharmacies generally may not compound with it.
- Also known as
- SNAP-8
- FDA approval
- Not FDA-approved for any use
- 503B outsourcing
- Not determined
- Anti-doping (WADA)
- Not on the WADA Prohibited List
- DEA schedule
- Not a controlled substance
About peptide status
Most peptides discussed here are not FDA-approved for any use, and products labeled “research use only” are not for human use. Removal from Category 2 does not authorize compounding. PCAC votes are non-binding recommendations; FDA and HHS make the final decisions.
This is not medical or legal advice, and we do not publish dosing, sourcing or reconstitution information. Talk with a licensed clinician before using any peptide.
If you think you are having a medical emergency, call 911.
Key takeaway
Acetyl octapeptide-3, sold in skincare as SNAP-8, is a synthetic eight-amino acid peptide modeled on the nerve protein SNAP-25 and marketed as a stronger successor to Argireline for softening the appearance of expression lines. Like Argireline, it is designed to interfere with the SNARE complex that nerves use to trigger muscle contraction, but its own published human evidence is thin and comes mostly from the manufacturer. It is a cosmetic ingredient rather than a drug, so it does not require FDA approval, and its evidence is rated Low.
At a glance
- What it is
- Synthetic peptide used in anti-aging skincare, best known by the trade name SNAP-8
- How it works
- "Neurotransmitter-inhibiting" peptide modeled on the nerve protein SNAP-25, marketed as a more potent version of Argireline for expression lines
- FDA status
- Cosmetic ingredient rather than a drug, so does not require FDA approval
- Evidence strength
- Low research
Summary
Acetyl octapeptide-3, sold as SNAP-8, is a cosmetic peptide marketed for expression lines. Learn how it works, how thin its evidence is, and its status.
What is acetyl octapeptide-3?
Acetyl octapeptide-3 is a synthetic eight-amino acid peptide used as a cosmetic ingredient, best known by the trade name SNAP-8. It is an elongated version of acetyl hexapeptide-8 (Argireline), with two extra amino acids. Like Argireline, acetyl octapeptide-3’s sequence is patterned on the end of SNAP-25, a protein that nerves use to release the signals that make muscles contract.
It is sold in serums and creams marketed for anti-aging and is a topical application.
How does it work?
Acetyl octapeptide-3 softens the look of expression lines by reducing the small muscle contractions that create them. Nerves trigger those contractions by releasing a chemical signal, and that release depends on a group of proteins called the SNARE complex, of which SNAP-25 is a part. In laboratory studies, peptides in this family mimic the end of SNAP-25 and compete with it, which interferes with SNARE complex formation and reduces the release of the signal that tells the muscle to contract. It is marketed as more potent than Argireline, though it is still a topical, far milder approach than an injection like Botox.
As with other topical peptides, a major limit is delivery. How well a large, water-loving peptide crosses the skin barrier to reach the nerves underneath is uncertain, and that caps how strong the effect can be.
Is it FDA-approved?
Safety note
Status: Cosmetic ingredient rather than a drug, so does not require FDA approval
Category: Cosmetic and topical · Primary body area: Skin & aging
No, and it does not need to be. The FDA does not approve cosmetics or most cosmetic ingredients before they go on the market. Cosmetics are regulated and must be safe when used as directed and properly labeled, but there is no pre-market approval step the way there is for drugs, so no anti-aging peptide in a serum is "FDA-approved."
The line that actually matters for an ingredient like this is the difference between a cosmetic and a drug. A product is a cosmetic when it is intended to improve appearance, but if it claims to change the structure or function of the skin, such as a claim to paralyze muscles, the FDA can regulate it as an unapproved drug. This is why skincare claims are written around the appearance of lines rather than a promised physiological change.
What is it used for?
Acetyl octapeptide-3 is used almost entirely in topical anti-aging products, where it is included to soften the appearance of expression lines, especially forehead lines and the crow's feet around the eyes. It is often marketed as a next-generation alternative to Argireline.
What does the research show?
Editor’s note
Evidence strength: Low research
Its human evidence is limited mainly to manufacturer testing, with no independent, peer-reviewed clinical trial, so the cosmetic benefit is largely unverified despite a plausible mechanism shared with Argireline.
The published human evidence for acetyl octapeptide-3 is thin. Most of the efficacy data comes from the ingredient's manufacturer, which reports reductions in the depth of wrinkles, rather than from independent, peer-reviewed clinical trials. Its close relative Argireline has a published randomized trial, but acetyl octapeptide-3 has not been tested to the same standard, so its benefit rests largely on manufacturer testing and its shared mechanism rather than strong independent evidence.
What are the side effects?
Topical acetyl octapeptide-3 is generally considered well tolerated, with the low potential for irritation typical of cosmetic peptides. As with any skincare ingredient, some people can still experience mild redness, irritation, or an allergic reaction, so a patch test before regular use is sensible. Because the peptide is applied to the skin rather than injected, its safety considerations are those of a typical cosmetic ingredient.
How does acetyl octapeptide-3 compare to acetyl hexapeptide-8?
Acetyl octapeptide-3 and acetyl hexapeptide-8 (Argireline) are close relatives, and the main practical difference between them is the strength of their published evidence rather than how they work. Both are synthetic peptides patterned on SNAP-25, and both are designed to interfere with the SNARE complex so that nerves release less of the signal behind the small muscle contractions that create expression lines. Where they part ways is structure and evidence:
| Attribute | Acetyl hexapeptide-8 (Argireline) | Acetyl octapeptide-3 |
|---|---|---|
| Length | 6 amino acids | 8 amino acids |
| Origin | The original, shorter peptide | An elongated version developed later and marketed as a more potent successor |
| Independent human evidence | Independent, peer-reviewed human studies, including a randomized controlled trial and a later randomized study that reported improvement in the appearance of wrinkles | Not tested to that standard; its efficacy data comes mostly from the manufacturer rather than independent trials |
So while acetyl octapeptide-3 is often sold as the stronger of the two, that "more potent" positioning is a marketing claim rather than a finding from a head-to-head study, and no published trial shows that one softens the look of lines better than the other in people. This gap in independent evidence is why Argireline sits at Moderate research while acetyl octapeptide-3 sits at Low.
Sources: the mechanism of this peptide family is described in the 2013 randomized controlled trial of the related peptide argireline (Wang et al., American Journal of Clinical Dermatology, DOI: 10.1007/s40257-013-0009-9, and a 2017 randomized study of acetyl hexapeptide-3 (Raikou et al., Journal of Cosmetic Dermatology, DOI: 10.1111/jocd.12314), both indexed on PubMed; and FDA guidance on how cosmetics are regulated. This document is educational and does not constitute medical advice or a treatment claim.
Registered human trials
0 registered human trials on ClinicalTrials.gov that we reviewed
Sources
- [1]
- [2]
- [3]
- [4]
Compare every peptide’s status in the peptide regulatory status database
More for Skin & aging
View all skin & aging peptides →- Cosmetic & topical Skin & aging
Acetyl-Hexapeptide-8
Argireline
Acetyl hexapeptide-8, sold in skincare as Argireline, is a synthetic peptide modeled on the nerve protein SNAP-25 and marketed as a topical, "Botox-like" way to soften the appearance of expression lines. In lab and small clinical studies it interferes with the SNARE complex that nerves use to trigger muscle contraction, and a 2013 randomized study found it reduced the appearance of peri-orbital wrinkles over four weeks. It is a cosmetic ingredient rather than a drug, so it does not require FDA approval, and its evidence is rated Moderate.
- Cosmetic & topical Skin & aging
Acetyl-Tetrapeptide-5
Eyeseryl
Acetyl tetrapeptide-5, sold in skincare as Eyeseryl, is a synthetic four-amino acid peptide used in eye creams to soften the look of under-eye bags and puffiness. It is thought to work in two ways, by easing the fluid buildup that makes the under-eye area look swollen and by limiting the glycation that stiffens collagen, though its published evidence comes almost entirely from the manufacturer. It is a cosmetic ingredient rather than a drug, so it does not require FDA approval, and its evidence is rated Low.
- FDA-approved Skin & aging
Afamelanotide
Afamelanotide is a synthetic, longer-lasting analog of alpha-melanocyte-stimulating hormone (α-MSH) that activates the MC1R receptor on pigment cells to boost the skin's own protective eumelanin. The FDA approved it in 2019 as Scenesse, a subcutaneous implant for adults with erythropoietic protoporphyria (EPP), a rare light-sensitivity disorder. In the pivotal 2015 placebo-controlled trials, U.S. patients (94) logged a median 69.4 pain-free hours in direct sunlight versus 40.8 on placebo (P = 0.04). EU patients (74) logged 6.0 versus 0.8 hours (P = 0.005).
- FDA-approved Skin & aging
Bacitracin
Bacitracin is a cyclic polypeptide antibiotic produced by Bacillus bacteria that kills gram-positive bacteria by blocking the construction of their cell wall. It is best known as an over-the-counter topical ointment for preventing infection in minor cuts, scrapes, and burns, often combined with neomycin and polymyxin B in "triple antibiotic" products. It is widely available over the counter, but it is also a common cause of allergic skin reactions, and its injectable form was withdrawn over kidney-toxicity concerns.
- Cosmetic & topical Skin & aging
Carnosine
Carnosine is a naturally occurring dipeptide, made of the amino acids beta-alanine and histidine, used in skincare as an antioxidant ingredient. Laboratory and ex-vivo skin studies suggest it can neutralize reactive oxygen species and limit glycation, a process in which sugars stiffen skin proteins, which is the rationale for using it in products aimed at the appearance of aging skin. As of 2026, the evidence for topical carnosine is largely from lab and ex-vivo studies rather than large human appearance trials.
- Cosmetic & topical Skin & aging
Copper-Tripeptide-1
GHK-Cu
Copper tripeptide-1, often called GHK-Cu, is a three-amino acid peptide (glycine-histidine-lysine) bound to a copper ion and used in skincare for its proposed role in skin renewal. Laboratory and animal studies show it can signal cells to make collagen and other matrix components. Independent human evidence is thin. In a randomized trial of 13 patients after CO2 laser resurfacing, GHK-Cu skincare showed no significant difference in redness or skin quality in blinded evaluations, though patients rated their overall skin quality higher (p = 0.04). As of 2026 it is a cosmetic ingredient, not an FDA-approved drug.